Hemorrhagic Risk of Transrectal Ultrasound‐Guided Prostate Biopsy Under Continued Antithrombotic Therapy
International Journal of Urology · 2026-04 · 33 (4)
DOI: 10.1111/iju.70462 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, online erschienen am 13.04.2026. Verfasst von Naoki Akagi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan. Hauptthemen laut MEDLINE: Prostate, Image-Guided Biopsy, Fibrinolytic Agents, Postoperative Hemorrhage. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Objectives
To evaluate the safety of transrectal ultrasound (TRUS)‐guided prostate biopsy performed without interruption of antithrombotic therapy.
Methods
In this single‐center retrospective study, we analyzed 2394 consecutive patients who underwent TRUS‐guided prostate biopsy under sacral (caudal) anesthesia between July 2011 and March 2023. Patients were classified according to antithrombotic status at biopsy: no antithrombotic therapy, antiplatelet therapy, or anticoagulant therapy. Hemorrhagic complications were graded using the Clavien–Dindo classification. The primary endpoint was any Clavien–Dindo grade II or higher hemorrhagic complication; grade II and grade III events were also examined. Multivariable logistic regression analyses were performed with antithrombotic status as the main explanatory variable and age and platelet count as covariates.
Results
Overall, 29 patients (1.2%) developed Clavien–Dindo grade II or higher hemorrhagic complications: 1.1% in the no antithrombotic group, 1.5% in the antiplatelet group, and 2.5% in the anticoagulant group. Neither antiplatelet nor anticoagulant therapy was associated with a significant increase in hemorrhagic complications compared with no antithrombotic therapy. No thromboembolic events were observed.
Conclusions
TRUS‐guided prostate biopsy under sacral anesthesia appeared feasible without discontinuation of antithrombotic therapy and was not associated with a clear excess of clinically significant hemorrhagic complications. In selected patients, particularly those at high thromboembolic risk, continuing antithrombotic therapy may be a reasonable option, although a modest increase in bleeding risk cannot be definitively excluded.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan.
ORCID-Profile: Masashi Kubota, Hiroki Hagimoto, Yuto Hattori, Yoichiro Tohi, Takashi Matsuoka, Mutsushi Kawakita
Zitieren
APA
Akagi, N., Nagoshi, A., Kubota, M., Hagimoto, H., Hattori, Y., Makita, N., Suzuki, R., Suzuki, I., Akahane, M., Abe, Y., Fukunaga, A., Tohi, Y., Kono, Y., Matsumoto, K., Matsuoka, T., Tsutsumi, N., Utsunomiya, N., Shibasaki, N., Kawakita, M., & Yamasaki, T. (2026). Hemorrhagic Risk of Transrectal Ultrasound‐Guided Prostate Biopsy Under Continued Antithrombotic Therapy. International Journal of Urology, 33(4). https://doi.org/10.1111/iju.70462
Vancouver
Akagi N, Nagoshi A, Kubota M, Hagimoto H, Hattori Y, Makita N, et al. Hemorrhagic Risk of Transrectal Ultrasound‐Guided Prostate Biopsy Under Continued Antithrombotic Therapy. International Journal of Urology. 2026;33(4). doi:10.1111/iju.70462
BibTeX
@article{Akagi2026,
author = {Akagi, Naoki and Nagoshi, Akihiko and Kubota, Masashi and Hagimoto, Hiroki and Hattori, Yuto and Makita, Noriyuki and Suzuki, Ryosuke and Suzuki, Issei and Akahane, Mizuho and Abe, Yohei and Fukunaga, Arinobu and Tohi, Yoichiro and Kono, Yuka and Matsumoto, Keiyu and Matsuoka, Takashi and Tsutsumi, Naohumi and Utsunomiya, Noriaki and Shibasaki, Noboru and Kawakita, Mutsushi and Yamasaki, Toshinari},
title = {Hemorrhagic Risk of Transrectal Ultrasound‐Guided Prostate Biopsy Under Continued Antithrombotic Therapy},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {4},
doi = {10.1111/iju.70462}
}
EUVIMED